

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,902,733 B2  
DATED : June 7, 2005  
INVENTOR(S) : Désire José Collen

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page, Item [54] and Column 1, lines 1-2,

Title, "STAPHYLOKINASE DERIVATIVES WITH POLYETHYLENEGLYCOL"  
should read -- STAPHYLOKINASE DERIVATIVES --.

Column 2,

Line 24, "SUMMARY OF TEE INVENTION" should read -- SUMMARY OF THE  
INVENTION --.

Column 3,

Line 17, "(open squares, n-6)" should read -- (open squares, n=6) --.

Line 23, "Squares: single amine acid" should read -- Squares: single amino acid --.

Line 30, "(•): 40°C" should read -- (•): 4°C --.

Line 30, "(V): 37" should read -- (∇): 37 --.

Line 34, "following nitra-arterial" should read -- following intra-arterial --.

Column 6,

Line 7, after "ID NO: 2).", insert the following:

-- The forward and backward primers shared an overlap of around 24 bp (primers not shown).  
The two purified fragments were then assembled together in a new primerless PCR using  
Taq polymerase (Boehringer Mannheim). After 7 cycles (1 min at 94°C, 1 min 55°C, 1 min  
at 72°C). The final product was purified, digested with EcoRI and HindIII and cloned into  
the corresponding sites of pMEX602sakB. --.

Column 10,

Line 5, "R46177A" should read -- R77A --.

Column 11,

Line 52, "Qiager" should read -- Qiagen --.

Column 12,

Line 1, "SakSTAR(187A) should read -- SakSTAR(I87A) --.

Line 5, "tmplate" should read -- template --.

Line 54, "(5' CAAACAGCCAAGCTTCATTCATTCAC)" should read  
-- (5' CAAACAGCCAAGCTTCATTCATTCAGC) --.

Line 61, "HindII" should read -- HindIII --.

Column 13,

Line 10, "at 0C" should read -- at 0°C --.

Lines 60 and 62, "with >3" should read -- with  $\geq 3$  --.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,902,733 B2  
DATED : June 7, 2005  
INVENTOR(S) : Désire José Collen

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 17,

Line 60, "Thrombolvtic Efficacy" should read -- Thrombolytic Efficacy --.

Column 18,

Line 57, "defied as neutralizing" should read -- defined as neutralizing --.

Line 59, "SakSTAR (K74Q80A)" should read -- SakSTAR (K74QE80A) --.

Column 20,

Beginning at line 2 and ending at line 36, delete the paragraph and insert the following:

The variants SakSTAR(K102C) and SakSTAR(K109C), were constructed by the spliced overlap extension polymerase chain reaction (SOE-PCR) (24) using *pMEX.SakSTAR* encoding SakSTAR as template. Two fragments were amplified by PCR (30 cycles: 1 sec at 94°C, 1 sec at 50°C, 10 sec at 72°C), the first one starting from the 5' end (primer 818A) of the *staphylokinase* gene to the region to be mutagenized (forward primer), the second one from this same region (backward primer) to the 3' end of the gene with primer 818D (5' CAAACAGCCCAAGCTTCATTCATTCAGC) (SEQ ID NO: 5). The forward and backward primers shared an overlap of around 24 bp (for the construction of K102C: TAT GAT AAG AAT TGC AAA AAA GAA GAA (backward) (SEQ ID NO: 6) and TTC TTC TTT TTT GCA ATT CTT ATC ATA (forward) (SEQ ID NO: 7) for the construction of K109C: AAA AAG AAG AAA CGT GCT CTT TCC CTA (backward) (SEQ ID NO: 8) and TAG GGA AAG AGC ACG TTT CTT CTT TTT (forward) (SEQ ID NO: 9). The two purified fragments were then assembled together in a second PCR reaction with the external primers 818A and 818D (30 cycles: 1 sec at 94°C, 1 sec at 50°C, 10 sec at 72°C). The amplified product from this final reaction was purified, digested with EcoRI and HindIII and ligated into the corresponding site of *pMEX.SakSTAR*. For each construction, the sequence of the variant was confirmed by sequencing the entire SakSTAR coding region.

Column 21,

Line 57, "period was < 5%" should read -- period was  $\leq 5\%$  --.

Line 59, "C50)" should read -- C<sub>50</sub>) --.

Column 22,

Line 34, "3.6 and ... min" should read -- 3.6 and 3.0 min --.

Line 35, "0.52 and ... mL/min" should read -- 0.52 and 0.32 mL/min --.

Line 39, "to size-eclusion" should read -- to size-exclusion --.

Column 23,

Lines 5-6, delete "(Pool 10)=(Pool 40)+..., with r= ...." and insert in its place -- (Pool 40) = 0.84 x (Pool 10), with r=0.94 and n=61. --.

Line 15, "specific activities > 200" should read -- specific activities  $\geq 200$  --.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,902,733 B2  
DATED : June 7, 2005  
INVENTOR(S) : Désire José Collen

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 24,

Line 50, "only ... of the ... patients" should read -- only 1 of the 6 patients --.

Lines 51-52, "of ... %" should read -- rate with the variants --.


Line 54, delete "(p=... by Fisher's exact text)" and insert in its place -- (p = 0.01 by 2 x 3 CHI<sup>2</sup> analysis --.

Column 59,

Line 4, "within up to" should read -- with up to --.

Signed and Sealed this

Seventh Day of February, 2006

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a cursive "Dudas".

JON W. DUDAS  
*Director of the United States Patent and Trademark Office*